Ionis Pharmaceuticals has delayed the primary completion of its Phase 1/2a trial for prion disease treatment to February 2027. The California-based oligonucleotide company had previously set an earlier timeline for the study completion.
Prion diseases are rare, progressive neurodegenerative disorders that are typically fatal. These conditions affect both humans and animals, with no currently approved treatments available, making any potential therapeutic development significant for patients and families affected by these conditions.